Stock comparison
Harmony Biosciences Holdings
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 69B | MTD |
| Benjamin Graham | 60C | 65B | MTD |
| Philip Fisher | 75B | 63C | HRMY |
| Peter Lynch | 62C | 66B | MTD |
| Joel Greenblatt | 28F | 68B | MTD |
| Charlie Munger | 62C | 74B | MTD |
| Terry Smith | 67B | 70B | MTD |
Side-by-side metrics
| Metric | HRMY | MTD |
|---|---|---|
| Market cap | $1.75B | $22.29B |
| P/E (TTM) | 11.8x | 25.3x |
| EV/EBIT | 6.4x | 21.6x |
| ROIC (TTM) | 12.5% | 36.09% |
| Gross margin | 76.55% | 57.79% |
| Net margin | 16.2% | 21.4% |
| Revenue CAGR 5y | 29.85% | 2.01% |
| EPS CAGR 5y | 46.45% | 6.12% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- Revenue CAGR 5y29.85%vs 2.01%+93%
- EPS CAGR 5y46.45%vs 6.12%+87%
- EV/EBIT6.4xvs 21.6x+70%
- P/E (TTM)11.8xvs 25.3x+53%
MTD leads on
- Debt / Equity-vs 0.2x+100%
- Market cap$22.29Bvs $1.75B+92%
- ROIC (TTM)36.09%vs 12.5%+65%
- Net margin21.4%vs 16.2%+24%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.